Pure Global
NCT04480125

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

The Efficacy and Safety of Azacitidine in Combination With Chidamide in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma Unfit for Conventional Chemotherapy
Ruijin Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
Azacitidine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ruijin Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
Jun 20, 2020
End date
Jun 20, 2024
Enrollment
28 participants
Primary outcome

Complete response rate

Summary

This prospective, open-label, single-arm study will evaluate the efficacy and safety of
 azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell
 lymphoma unfit for conventional chemotherapy.

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04480125
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04480125 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ruijin Hospital and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.